What the PI3K Pathway Does
The PI3K pathway is a chain of molecular signals that tells a cell to grow, divide, and survive. When growth factors bind to receptors on the cell surface, PI3K enzymes are activated and convert a membrane lipid called PIP2 into PIP3. That small chemical change recruits downstream proteins, including AKT, which then push the cell forward through the cell cycle and block self-destruction. In healthy tissues, this pathway is tightly controlled and activated only when the body needs it.
More from this site
Keep reading the latest coverage
Because it sits at the crossroads of metabolism, proliferation, and survival, the PI3K pathway is one of the most studied routes in cancer biology. When it works correctly, it supports normal development and tissue repair. When it is broken, it can drive tumor formation and resistance to treatment.
Core Components of the Pathway
The pathway has three main layers: receptors, lipid kinases, and downstream effectors.
- Receptors: Receptor tyrosine kinases such as EGFR, HER2, and insulin receptors trigger PI3K when bound by their ligands.
- PI3K enzymes: The class I PI3K family (PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ) are the central lipid kinases. They are made of a catalytic subunit (p110) and a regulatory subunit (p85).
- Downstream nodes: PIP3 recruits AKT (protein kinase B), which then activates mTORC1 to promote protein synthesis and growth, while also inhibiting pro-apoptotic factors.
- Negative regulators: PTEN phosphatase removes the phosphate from PIP3, turning the signal off. Loss of PTEN is one of the most common ways the pathway becomes hyperactive.
How the PI3K Pathway Drives Cancer
Cancer cells hijack the PI3K pathway at many points. Activating mutations in PIK3CA (which encodes the p110α catalytic subunit) are among the most frequent alterations in human tumors. Loss-of-function mutations in PTEN remove the brake on the pathway entirely. Amplifications or mutations in AKT or mTOR can keep the signal running even when upstream receptors are blocked. These changes make tumor cells addicted to PI3K signaling for survival and growth.
The pathway also helps tumors resist therapies. When a targeted drug blocks one receptor or kinase, cancer cells often reroute through PI3K to stay alive. That is why PI3K pathway inhibitors are being developed not just as single agents but in combination strategies.
PI3K Inhibitors and Current Therapies
Several types of drugs now target the pathway at different levels.
- Pan-class I PI3K inhibitors: Drugs like idelalisib and copanlisib block multiple PI3K isoforms and are approved for certain blood cancers such as chronic lymphocytic leukemia and follicular lymphoma.
- PI3Kα-selective inhibitors: Alpelisib targets the p110α subunit and is approved for PIK3CA-mutant breast cancer, often given with endocrine therapy.
- Dual PI3K/mTOR inhibitors: Apitolisib and dactolisib aim to block both PI3K and mTOR to prevent feedback reactivation, though clinical results have been mixed so far.
- AKT inhibitors: Ipatasertib and capivasertib directly inhibit AKT and are in trials for tumors with PTEN loss or PI3K activation.
Choosing which inhibitor to use depends on the tumor's genetic profile. Testing for PIK3CA mutations, PTEN status, and AKT or mTOR alterations helps oncologists decide whether a PI3K-targeted therapy is appropriate.
Resistance Mechanisms and Future Directions
Resistance remains the biggest challenge. Tumors can develop new mutations in PI3K or reactivate the pathway through alternative receptors such as IGF1R. Cross-talk with the RAS-RAF-MEK-ERK pathway can also bypass PI3K blockade entirely. Researchers are working on next-generation inhibitors that are more selective, better tolerated, and active against resistant mutations. Biomarker-driven trials that match patients to PI3K pathway drugs based on their tumor's molecular profile are becoming standard practice and are expected to improve outcomes.
The Bottom Line
The PI3K pathway is a master regulator of cell growth and survival. Its frequent dysregulation in cancer makes it a high-value target, and a growing number of inhibitors are already in clinical use or late-stage trials. Success depends on understanding which part of the pathway is broken in a given tumor and combining drugs intelligently to overcome resistance. For patients, molecular testing of tumors for PI3K pathway alterations is now a routine step that can open doors to more precise treatment options.